Osimertinib in first line setting: for Asian patients

समान संसाधन

• Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study)
  द्वारा: Chihara, Yusuke, और अन्य
  प्रकाशित: (2019)
• Osimertinib in first line setting: preventive or delayed T790M occurrence?
  द्वारा: Sun, Hao, और अन्य
  प्रकाशित: (2018)
• First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
  द्वारा: Ricciuti, Biagio, और अन्य
  प्रकाशित: (2018)
• Osimertinib in first-line treatment—is a comparison not proof?
  द्वारा: Cadranel, Jacques
  प्रकाशित: (2018)
• First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
  द्वारा: Jeong, Byeong-Ho, और अन्य
  प्रकाशित: (2018)